Victoria Dardov is currently a doctoral candidate. In 2011, she graduated with a bachelor's degree in physiology and neuroscience from the University of California, San Diego (UCSD). During her undergraduate studies, she was a student researcher at the UCSD Moores Cancer Center and later obtained an internship at Vertex Pharmaceuticals. After graduation, Dardov worked as a research associate at Vertex and developed medicinal chemistry assays for the Huntington's team and oversaw automated production of human bronchial epithelial cultures for the cystic fibrosis program. She transitioned to the Genomics Institute of the Novartis Research Foundation and joined the Advanced Automation Technologies team, operating an ultra-high-throughput automated assay platform for drug discovery. In 2014, she joined the Cedars-Sinai PhD program. The following year, she joined two research laboratories for a co-mentoring, collaborative project with Clive Svendsen, PhD, and Jennifer Van Eyk, PhD. Dardov’s doctorate research focuses on proteomic and post-translational modification changes in amyotrophic lateral sclerosis (ALS) and uses induced pluripotent stem cell derived ALS models.